ScreenerHero

APREAprea Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · aprea.com
0.6403USD-4.58%Mkt Cap: 8.06M $P/E: —

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead prod…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap8.06M $
Enterprise Value-32.45M $
Revenue (TTM)5.18K $
Gross Profit-6.72M $
Net Income (TTM)-12.60M $
Revenue/Share0.0000 USD
Last Price0.6403 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees8
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.21
PEG—
EV/EBITDA2.46
EV/Revenue-6257.88
P/S1554.16
P/B0.21
EPS (TTM)-0.87
EPS (Forward)-0.29
52W Range
0.54808% of range1.750
52W High1.750 USD
52W Low0.5480 USD
Profitability
Gross Margin0.00%
Oper. Margin-255025.51%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-101.27%
ROA-79.08%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.89M $
CapEx (TTM)—
FCF Margin-157217.76%
FCF Yield-101.11%
Net Debt-41.23M $
Net Debt/EBITDA3.12
Balance Sheet
Debt/Equity—
Current Ratio13.55
Quick Ratio13.33
Book Value/Sh3.105 USD
Cash/Share3.275 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateFeb 13, 2023
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.550 USD
Upside (mean)+454.4%
Target Range1.200 USD – 5.000 USD
$1.200+454.4% to mean$5.000
# Analysts4
Ownership
Shares Out.12.59M
Float7.83M
Insiders13.23%
Institutions18.83%
Short Interest
Short Ratio0.7d
Short % Float0.35%
Short % Out.0.33%
Shares Short41.08K
Short (prev mo.)77.80K
Technical
SMA 500.7000 (-8.5%)
SMA 2000.8428 (-24.0%)
Beta1.59
S&P 52W Chg18.16%
Avg Vol (30d)47.61K
Avg Vol (10d)31.02K
Technical Indicators
RSI (14)43.6
MACD-0.0093
MACD Signal-0.0175
MACD Hist.+0.0082
BB Upper0.6954 USD
BB Middle0.6409 USD
BB Lower0.5864 USD
BB Width17.00%
ATR (14)0.0539 USD
Vol Ratio (20d)0.31x